A detailed history of Bank Of America Corp transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Bank Of America Corp holds 1,002,290 shares of DVAX stock, worth $12.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,002,290
Previous 1,013,097 1.07%
Holding current value
$12.3 Million
Previous $12.6 Million 10.48%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$10.73 - $12.58 $115,959 - $135,952
-10,807 Reduced 1.07%
1,002,290 $11.3 Million
Q1 2024

May 15, 2024

BUY
$11.7 - $14.98 $6.63 Million - $8.49 Million
566,745 Added 126.97%
1,013,097 $12.6 Million
Q4 2023

Feb 14, 2024

SELL
$13.09 - $14.98 $14 Million - $16 Million
-1,067,363 Reduced 70.51%
446,352 $6.24 Million
Q2 2023

Aug 14, 2023

SELL
$9.85 - $13.17 $27.8 Million - $37.2 Million
-2,826,572 Reduced 65.12%
1,513,715 $19.6 Million
Q1 2023

May 12, 2023

BUY
$9.44 - $11.88 $36.5 Million - $45.9 Million
3,864,170 Added 811.6%
4,340,287 $42.6 Million
Q4 2022

Feb 10, 2023

BUY
$10.27 - $13.29 $413,798 - $535,480
40,292 Added 9.24%
476,117 $5.07 Million
Q3 2022

Nov 14, 2022

BUY
$9.93 - $17.44 $3.25 Million - $5.71 Million
327,531 Added 302.45%
435,825 $4.55 Million
Q2 2022

Aug 12, 2022

SELL
$7.45 - $12.83 $3.98 Million - $6.86 Million
-534,866 Reduced 83.16%
108,294 $1.36 Million
Q1 2022

May 16, 2022

BUY
$9.75 - $14.44 $3.12 Million - $4.63 Million
320,398 Added 99.27%
643,160 $6.97 Million
Q4 2021

Feb 08, 2022

BUY
$13.17 - $20.94 $3.32 Million - $5.28 Million
251,995 Added 356.09%
322,762 $4.54 Million
Q3 2021

Nov 15, 2021

SELL
$9.16 - $19.83 $43,619 - $94,430
-4,762 Reduced 6.3%
70,767 $1.36 Million
Q2 2021

Sep 13, 2021

BUY
$7.25 - $10.99 $547,585 - $830,063
75,529 New
75,529 $744,000

Others Institutions Holding DVAX

About DYNAVAX TECHNOLOGIES CORP


  • Ticker DVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 126,474,000
  • Market Cap $1.55B
  • Description
  • Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
More about DVAX
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.